Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Device: CGMDevice: SMBG
- Registration Number
- NCT03620357
- Lead Sponsor
- DexCom, Inc.
- Brief Summary
A Study to assess if patients with Type 2 diabetes (T2D) who have suboptimal glycemic control using multiple oral agents are able to make lifestyle changes resulting in improved glycemic control by use of real-time continuous glucose monitoring (RT-CGM) and targeted learning modules versus self monitored blood glucose (SMBG) testing.
- Detailed Description
The study is referred to as "Continuous Glucose Monitoring and Management in Type 2 Diabetes" also known as The COMMITED Study" and will assess if patients with Type 2 diabetes (T2D) who have suboptimal glycemic control using 2 or more multiple oral agents are able to make lifestyle changes resulting in improved glycemic control by use of real-time continuous glucose monitoring and targeted learning modules.
At time of enrollment, participants will undergo a run-in period of blinded CGM for a duration of 10 days to collect baseline data. Baseline Patient Report Outcome (PRO) surveys will be administered at the start of run-in.
The study design includes a run-in phase, a study phase and a follow up visit. During the study phase, participants will be randomized into two groups - CGM Group or SMBG Group. For the RT-CGM Group, the study comprises of 4 scheduled clinic visits at baseline (after Run-In), week 4, week 8, and week 12 to collect data on episodic RT-CGM use. During these visits, RT-CGM insertions will take place at baseline, week 4 and week 8 clinic visits, with each wear period lasting a duration of 10 days. For the SMBG Group, the study comprises of 3 scheduled clinic visits at baseline (after Run-In), week 8 (to collect data on episodic blinded CGM use) and week 12. CGM insertions will take place at week 8 with a wear period of 10 days. Both groups will have HbA1c collected at week 0 and week 12. The same PRO surveys administered at start of run-in will be administered again at week 12. There will not be therapeutic changes during the study phase unless needed for safety.
There will be phone/remote visits by a study site clinician at weeks 2, 6 and 10 in both groups to review the SMBG or CGM data. During these remote visits, there will be discussions about what the subjects have learned from their glucose monitoring and what the study clinician has observed.
All subjects will be scheduled for a follow up visit at Month 9 to obtain local lab or POC HbA1c. Diabetes medications (classifications only) will also be collected.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 72
- Age at least 30 years
- Diagnosis of T2D treated with 2 or more oral anti-diabetic medications
- HbA1c ≥ 7.8 and ≤10.5% by local lab or POC
Major
- Using insulin
- Pregnancy
- Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m2
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Continuous Glucose Monitor (CGM) Group CGM - SMBG Group SMBG -
- Primary Outcome Measures
Name Time Method HbA1c From baseline to Month 3 (Week 12) The primary endpoint is defined as change in HbA1c (determined by local lab or POC results).
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (10)
Diabetes/Lipid Management and Research Center
🇺🇸Huntington Beach, California, United States
Temecula Valley Endocrinology
🇺🇸Temecula, California, United States
MODEL Clinical Research (Towson)
🇺🇸Baltimore, Maryland, United States
Atlanta Diabetes Associates
🇺🇸Atlanta, Georgia, United States
Las Vegas Endocrinology
🇺🇸Henderson, Nevada, United States
Diabetes & Endocrine Associates, PC
🇺🇸Omaha, Nebraska, United States
Diabetes and Glandular Disease Clinic
🇺🇸San Antonio, Texas, United States
LMC Manna Research
🇨🇦Toronto, Ontario, Canada
Palm Research Center
🇺🇸Las Vegas, Nevada, United States
The Docs
🇺🇸Las Vegas, Nevada, United States